Magazine

"A Shot In The Arm For Cleveland BioLabs" (Inside Wall Street, Oct. 2, 2006)


In "A shot in the arm for Cleveland BioLabs" (Inside Wall Street, Oct. 2), Curaxins is in phase 2 trials, not phase 3, and has killed human cancer cells transplanted into animals, not primates. And Cleveland Clinic will provide the equivalent of $5 million in research and infrastructure.


We Almost Lost the Nasdaq
LIMITED-TIME OFFER SUBSCRIBE NOW

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

 
blog comments powered by Disqus